Literature DB >> 20067906

Effect of corticosteroids during ongoing drug exposure in pantoprazole-induced interstitial nephritis.

Min Jeong Kim1, Markus Heim, Michael Mayr.   

Abstract

Acute interstitial nephritis (AIN) represents a significant cause of acute renal failure in hospital practice. An increasing number of drugs are known to cause AIN. Due to the lack of prospective, randomized clinical trials, the most effective management is still uncertain, especially the role of steroids in the resolution of interstitial nephritis remains to be further defined. We report on a case with pantoprazole-induced interstitial nephritis and on the effect of steroids during ongoing drug exposure. In spite of ongoing drug exposure, steroids led to almost complete resolution of the inflammatory infiltrates. Early diagnosis of interstitial nephritis by renal biopsy and identification of the causative drug and its withdrawal remains the mainstay of treatment. However, the additional use of steroids has the potential to eradicate inflammatory infiltrates more rapidly and completely and may thus be important to minimize subsequent chronic damage.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20067906     DOI: 10.1093/ndt/gfp751

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  3 in total

1.  Pantoprazole-induced acute interstitial nephritis.

Authors:  Sheila Klassen; Joan C Krepinsky; Ally P H Prebtani
Journal:  CMAJ       Date:  2012-10-29       Impact factor: 8.262

2.  Pantoprazole-induced acute kidney injury: A case report.

Authors:  Tao Peng; Zhao Hu; Hongnan Zheng; Junhui Zhen; Chengjun Ma; Xiangdong Yang
Journal:  Exp Ther Med       Date:  2018-04-23       Impact factor: 2.447

3.  Inflammatory leucocyte infiltrates are associated with recovery in biopsy-proven acute interstitial nephritis: a 20-year registry-based case series.

Authors:  Ralph Wendt; Jennifer Schliecker; Joachim Beige
Journal:  Clin Kidney J       Date:  2019-08-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.